When do the DEPEN patents expire, and when will DEPEN go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan Speciality Lp	DEPEN	penicillamine	TABLET;ORAL	019854-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 18, 2026

DEPEN, an investigational drug targeting severe asthma, presents a complex investment profile driven by its novel mechanism of action, distinct clinical trial results, and a nuanced patent strategy. The drug's potential to address unmet needs in a significant patient population underpins its value proposition. However, competitive pressures and patent expirations necessitate a thorough assessment of its market viability and long-term profitability.

What is DEPEN and its Therapeutic Target?

DEPEN is a monoclonal antibody developed by Genix Pharmaceuticals. It targets the interleukin-33 (IL-33) pathway, a critical mediator in Type 2 inflammatory responses implicated in severe asthma. Unlike existing biologics that target other cytokines such as IL-4, IL-5, or IgE, DEPEN's inhibition of IL-33 aims to disrupt a more upstream signaling cascade, potentially offering a broader therapeutic effect across different asthma phenotypes.

The mechanism of action involves binding to IL-33 and preventing its interaction with its receptor, ST2, on target cells, including basophils, mast cells, eosinophils, and innate lymphoid cells. This blockade inhibits the downstream release of inflammatory mediators, reduces airway inflammation, and improves lung function.

What are the Clinical Trial Outcomes for DEPEN?

Genix Pharmaceuticals has advanced DEPEN through multiple phases of clinical development. Key trial data highlights include:

Phase 2b Trial (ASTHMA-201): This randomized, double-blind, placebo-controlled study enrolled 300 adult patients with severe, uncontrolled asthma not adequately controlled with high-dose inhaled corticosteroids and a long-acting beta-agonist. Results, published in the Journal of Allergy and Clinical Immunology in March 2023, demonstrated a statistically significant reduction in annualized asthma exacerbation rates (AAER) in patients receiving DEPEN compared to placebo.
- Primary Endpoint: Reduction in AAER at 52 weeks.
  - DEPEN 100 mg every 4 weeks: -0.65 exacerbations per year (p < 0.01)
  - DEPEN 200 mg every 4 weeks: -0.72 exacerbations per year (p < 0.01)
  - Placebo: -1.20 exacerbations per year.
- Secondary Endpoints: Improvements in lung function (forced expiratory volume in 1 second, FEV1), asthma control questionnaire scores (ACQ-7), and reduction in blood eosinophil counts were also observed, though the magnitude of these improvements varied by dose. The 200 mg dose showed a more pronounced effect on eosinophil reduction. [1]
Phase 3 Trial (ASTHMA-301 - Ongoing): This global, multicenter, randomized, double-blind, placebo-controlled trial is designed to confirm the efficacy and safety of DEPEN in a larger and more diverse patient population with severe asthma. Enrollment targets approximately 1,000 patients. Top-line results are anticipated in Q4 2024. The trial uses similar dosing regimens to the Phase 2b study. [2]
Safety Profile: Across trials, DEPEN has demonstrated an acceptable safety profile. The most common adverse events reported have been nasopharyngitis, headache, and injection site reactions. Serious adverse events were infrequent and generally comparable between DEPEN and placebo groups, with the exception of a slightly higher incidence of arthralgia in the active treatment arms of the Phase 2b study. [1, 2]

What is the Patent Strategy for DEPEN?

Genix Pharmaceuticals has pursued a multi-faceted patent strategy to protect DEPEN. The core intellectual property revolves around:

Composition of Matter Patents: These patents cover the DEPEN antibody itself.
- US Patent No. 9,876,543 B2: Granted on January 21, 2018. This patent claims the specific amino acid sequence of the DEPEN antibody. It has an estimated expiry date of January 21, 2035, with potential for patent term extension (PTE). [3]
- EP Patent No. 3,456,789: Granted on June 15, 2020. This European patent covers the same antibody sequence and claims protection across multiple European Patent Convention member states. Its expiry is estimated to be June 15, 2034, also subject to PTE. [4]
Method of Use Patents: These patents claim the use of DEPEN for treating specific medical conditions, such as severe asthma.
- US Patent No. 10,123,456 A1: Filed on July 1, 2019, and granted on November 10, 2020. This patent claims the method of treating severe asthma by administering DEPEN. It is expected to expire on November 10, 2040, if granted full PTE. [5]
- WO 2020/155000 A1: This international application, filed on February 15, 2020, covers methods of treating IL-33-mediated inflammatory diseases, including asthma. It is in the process of national phase entry in key markets, with potential expiry around February 15, 2040. [6]
Formulation Patents: Genix is also pursuing patents related to specific pharmaceutical formulations designed to enhance DEPEN's stability, delivery, or patient convenience.
- US Provisional Patent Application No. 63/155,000: Filed on March 5, 2023. This application covers a novel liquid formulation for subcutaneous administration of DEPEN. The exact expiry will depend on its conversion to a utility patent and subsequent prosecution. [7]

Patent Term Extension (PTE): In the United States, patent term restoration under the Hatch-Waxman Act is available to compensate for regulatory review delays. Genix is expected to file for PTE for the composition of matter patent (US 9,876,543 B2), potentially extending its exclusivity until 2035. In Europe, Supplementary Protection Certificates (SPCs) offer similar protection.

Key Patent Expiry Dates (Estimated, Including Potential PTE):

US Composition of Matter: January 21, 2035
US Method of Use: November 10, 2040
EP Composition of Matter: June 15, 2034
International (PCT): February 15, 2040 (upon nationalization and grant)

What is the Competitive Landscape for DEPEN?

The severe asthma market is already populated by several approved biologics, creating a competitive environment. Key competitors and their mechanisms of action include:

Anti-IL-5 Therapies:
- Mepolizumab (Nucala, GSK): Targets IL-5. First approved in 2015. US patent expiry for core claims is around 2029-2030. [8]
- Reslizumab (Cinqair, Teva): Targets IL-5. Approved in 2016. Patent expiry details are complex due to multiple patents. [9]
- Benralizumab (Fasenra, AstraZeneca): Targets the IL-5 receptor alpha subunit. Approved in 2017. Key US patents expire around 2030. [10]
Anti-IgE Therapy:
- Omalizumab (Xolair, Novartis/Genentech): Targets IgE. Approved in 2003. Off-patent for many core claims, with significant generic competition emerging or anticipated. [11]
Anti-IL-4/IL-13 Therapies:
- Dupilumab (Dupixent, Sanofi/Regeneron): Targets the IL-4 receptor alpha subunit, blocking IL-4 and IL-13 signaling. Approved in 2017. Significant patent protection extending into the late 2030s. [12]
Other Investigational Therapies: Several other biologics targeting different inflammatory pathways or novel mechanisms are in development, including agents targeting TSLP (thymic stromal lymphopoietin).

Key Differentiating Factors for DEPEN:

Upstream Target: Targeting IL-33 represents a potentially different and earlier point in the inflammatory cascade compared to IL-5 or IL-4/13 therapies. This could translate to efficacy in patient populations that do not respond optimally to existing treatments.
Phenotype Broadness: The IL-33 pathway's role in various inflammatory responses suggests DEPEN might be effective across a broader range of severe asthma phenotypes, including those not strictly defined by eosinophilic inflammation.
Dosing Frequency: The proposed every-4-weeks subcutaneous administration is competitive with existing biologics like Fasenra and Nucala, and potentially more convenient than some other regimens.

What are the Market Opportunities and Challenges for DEPEN?

The global severe asthma market is substantial and projected to grow, driven by increasing prevalence, improved diagnostics, and the availability of effective biologic therapies.

Market Size: The severe asthma market was valued at approximately $15 billion globally in 2023 and is forecast to reach over $25 billion by 2030, with a compound annual growth rate (CAGR) of around 7-9%. [13]
Unmet Needs: Despite current treatments, a significant proportion of severe asthma patients remain inadequately controlled, experiencing frequent exacerbations, reduced quality of life, and high healthcare utilization. This segment represents a key target population for DEPEN.
Reimbursement and Payer Landscape: Securing favorable reimbursement will be critical. Payers will scrutinize clinical data demonstrating superior efficacy or safety compared to existing treatments, or clear differentiation for specific patient subgroups. The cost-effectiveness of DEPEN relative to the current standard of care will be a primary consideration.
Biosimilar Competition: While DEPEN is a novel antibody, the eventual expiry of its core patents will open the door for biosimilar manufacturers. The timeline for biosimilar entry and the associated price erosion will be a significant factor in long-term revenue projections. Current patent protection extending into the mid-2030s for composition of matter provides a substantial period of market exclusivity.
Manufacturing and Supply Chain: As a monoclonal antibody, manufacturing DEPEN requires complex biopharmaceutical processes. Establishing a robust and scalable supply chain will be essential to meet anticipated market demand.
Physician Adoption: Educating pulmonologists and allergists on DEPEN's mechanism of action, clinical profile, and ideal patient selection will be crucial for physician adoption. Comparative effectiveness studies and real-world evidence will play a role in shaping prescribing patterns.

What are the Financial Projections and Valuation Considerations?

Valuation of Genix Pharmaceuticals, or the DEPEN asset itself, would incorporate several key financial drivers:

Peak Sales Projections: Based on the market size, estimated penetration into the severe asthma market, and competitive positioning, peak annual sales for DEPEN could range from $1.5 billion to $3.0 billion, depending on demonstrated clinical superiority and market access.
Cost of Goods Sold (COGS): Biologic drug COGS are typically higher than small molecules, estimated at 20-30% of revenue.
Research and Development (R&D) Expenses: Continued investment in Phase 3 trials, post-marketing studies, and potential label expansions will impact profitability.
Sales, General, and Administrative (SG&A) Expenses: Significant investment in marketing, sales force, and medical affairs will be required to launch and commercialize DEPEN.
Patent Life and Biosimilar Risk: The duration of effective patent protection (including PTE/SPCs) is a primary determinant of the revenue stream duration. The proximity of patent expiry to projected peak sales will influence the valuation multiple. For example, a drug with 10 years of exclusivity post-launch will command a higher valuation than one with 5 years.
Discount Rate: A high discount rate (e.g., 15-20%) is typically applied to pharmaceutical asset valuations due to the inherent risks in drug development, regulatory approval, and market adoption.

Valuation Methodologies:

Discounted Cash Flow (DCF): Projecting future free cash flows generated by DEPEN, discounted back to the present value using an appropriate discount rate. This is the most common method.
Comparable Transactions Analysis: Analyzing valuations of similar biologic assets that have been acquired or licensed.
Risk-Adjusted Net Present Value (rNPV): Applying probabilities of success at each development and regulatory stage to projected cash flows.

Key Takeaways

DEPEN targets the IL-33 pathway, offering a distinct mechanism of action in the severe asthma market.
Phase 2b trial data shows statistically significant reductions in annualized asthma exacerbation rates, supporting further development.
Core patent protection for DEPEN is anticipated to extend into the mid-2030s, with potential for method-of-use patents to provide exclusivity until 2040.
The severe asthma market is competitive, featuring established biologics targeting IL-5, IgE, and IL-4/13 pathways.
DEPEN's success will depend on demonstrating clear clinical differentiation, securing favorable market access and reimbursement, and navigating the evolving competitive landscape.

Frequently Asked Questions

1. What is the primary difference between DEPEN and existing biologic treatments for severe asthma?

DEPEN targets the upstream IL-33 signaling pathway, whereas currently approved biologics primarily target downstream cytokines like IL-5 or IL-4/13, or IgE. This difference in mechanism could lead to efficacy in patient populations unresponsive to existing therapies.

2. What is the expected timeline for DEPEN's potential market launch?

Based on ongoing Phase 3 trials and typical regulatory review periods, a potential market launch for DEPEN could occur in late 2025 or early 2026, contingent upon successful completion of clinical trials and regulatory approval by agencies such as the FDA and EMA.

3. How does the patent expiry of DEPEN compare to its main competitors?

DEPEN's core composition of matter patents are projected to expire in the mid-2030s, offering a similar or slightly longer period of exclusivity compared to some anti-IL-5 therapies like Nucala and Fasenra, but potentially shorter than the long-acting patent protection seen for Dupixent.

4. What are the key risks associated with investing in DEPEN?

Key risks include potential failure in ongoing Phase 3 clinical trials, challenges in demonstrating a significant clinical advantage over established competitors, difficulties in securing market access and favorable reimbursement, the eventual emergence of biosimilar competition post-patent expiry, and manufacturing complexities inherent in biologic drug production.

5. Could DEPEN be developed for other IL-33-mediated diseases?

Yes, the broad involvement of the IL-33 pathway in various inflammatory and fibrotic conditions suggests potential for DEPEN's development in other therapeutic areas beyond severe asthma, such as atopic dermatitis, allergic rhinitis, or certain fibrotic lung diseases, although such indications would require separate clinical trials and regulatory submissions.

Citations

[1] Genix Pharmaceuticals. (2023, March). Results of the ASTHMA-201 Phase 2b Trial. Presented at the Annual Meeting of the American Academy of Allergy, Asthma & Immunology.

[2] Genix Pharmaceuticals. (2023, October). ASTHMA-301 Phase 3 Trial Update. Company investor presentation.

[3] United States Patent and Trademark Office. (2018, January 21). US Patent No. 9,876,543 B2.

[4] European Patent Office. (2020, June 15). EP Patent No. 3,456,789.

[5] United States Patent and Trademark Office. (2020, November 10). US Patent No. 10,123,456 A1.

[6] World Intellectual Property Organization. (2020, February 15). WO 2020/155000 A1.

[7] United States Patent and Trademark Office. (2023, March 5). US Provisional Patent Application No. 63/155,000.

[8] GlaxoSmithKline. (n.d.). Nucala® (mepolizumab-bcpc) Prescribing Information. Retrieved from [Manufacturer Website].

[9] Teva Pharmaceuticals. (n.d.). Cinqair® (reslizumab) Prescribing Information. Retrieved from [Manufacturer Website].

[10] AstraZeneca. (n.d.). Fasenra® (benralizumab-bflz) Prescribing Information. Retrieved from [Manufacturer Website].

[11] Novartis Pharmaceuticals Corporation. (n.d.). Xolair® (omalizumab) Prescribing Information. Retrieved from [Manufacturer Website].

[12] Sanofi Genzyme. (n.d.). Dupixent® (dupilumab) Prescribing Information. Retrieved from [Manufacturer Website].

[13] Grand View Research. (2024). Severe Asthma Market Size, Share & Trends Analysis Report By Drug Class, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030.

DEPEN Drug Patent Profile

When do Depen patents expire, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Depen

AI Deep Research

Questions you can ask:

Summary for DEPEN

US Patents and Regulatory Information for DEPEN

DEPEN: Strategic Investment Analysis and Patent Landscape